To include your compound in the COVID-19 Resource Center, submit it here.

Nuedexta dextromethorphan/quinidine: Phase II data

The 10-week, double-blind, U.S. Phase II AVR-131 trial in 220 AD patients showed that oral AVP-923 met the primary endpoint of reducing agitation as measured by the agitation/aggression subscale score of the NPI vs.

Read the full 347 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE